Alex Wu
Hematology & Oncology · Brooklyn, NYNPI 1770978231
Payments from drug & device makers
Across 112 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$473
- Astellas Pharma US Inc$288
- Daiichi Sankyo Inc.$192
- Boehringer Ingelheim$191
- Eisai Inc.$189
- Sobi, Inc$154
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,49889%
- Education$32011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 9 | $473 |
| Astellas Pharma US Inc | 13 | $288 |
| Daiichi Sankyo Inc. | 8 | $192 |
| Boehringer Ingelheim | 7 | $191 |
| Eisai Inc. | 9 | $189 |
| Sobi, Inc | 7 | $154 |
| Stemline Therapeutics Inc. | 2 | $142 |
| Shield Therapeutics Inc | 7 | $141 |
| Puma Biotechnology, Inc. | 6 | $139 |
| Bayer | 7 | $134 |
| Bristol Myers Squibb | 6 | $122 |
| Johnson & Johnson | 5 | $116 |
| AstraZeneca | 5 | $104 |
| Agios Pharmaceuticals, Inc. | 4 | $80 |
| GSK | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Geron Corporation | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Merck | 1 | $25 |
| Sanofi | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Novartis | 1 | $21 |
| Amgen | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,818 in reported general payments places this provider in the 45th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $562,233 |
| TagrissoOsimertinib Mesylate | 25 | $423,263 |
| VerzenioAbemaciclib | 13 | $197,580 |
| ZejulaNiraparib Tosylate | 11 | $180,951 |
| OpdivoNivolumab | 17 | $119,659 |
| PromactaEltrombopag Olamine | 11 | $87,441 |
| NyvepriaPegfilgrastim-Apgf | 15 | $54,778 |
| ProcritEpoetin Alfa | 18 | $49,293 |
| XgevaDenosumab | 14 | $43,055 |
| Docetaxel | 19 | $25,124 |
| EliquisApixaban | 36 | $19,854 |
| Gemcitabine Hcl | 25 | $9,744 |
| VascepaIcosapent Ethyl | 17 | $9,298 |
| Aprepitant | 24 | $5,047 |
| RetacritEpoetin Alfa-Epbx | 11 | $1,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $33 | $562,23327 claims |
| AstraZenecaTagrisso | $104 | $423,26325 claims |
| Lilly USA, LLCVerzenio | $22 | $197,58013 claims |
| GSKZejula | $60 | $180,95111 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo | $42 | $119,65917 claims |
| NovartisPromacta | $21 | $87,44111 claims |
| Johnson & JohnsonProcrit | $116 | $49,29318 claims |
| AmgenXgeva | $20 | $43,05514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Brooklyn
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.